Aigen Investment Management LP Has $274,000 Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Aigen Investment Management LP trimmed its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 25.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,794 shares of the company’s stock after selling 1,990 shares during the period. Aigen Investment Management LP’s holdings in Kymera Therapeutics were worth $274,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Ameritas Investment Partners Inc. raised its position in shares of Kymera Therapeutics by 7.8% in the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock valued at $164,000 after purchasing an additional 295 shares during the period. Comerica Bank lifted its position in Kymera Therapeutics by 13.7% during the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after acquiring an additional 400 shares during the last quarter. Keudell Morrison Wealth Management boosted its holdings in shares of Kymera Therapeutics by 7.2% during the second quarter. Keudell Morrison Wealth Management now owns 7,105 shares of the company’s stock worth $212,000 after acquiring an additional 480 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Kymera Therapeutics by 27.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after purchasing an additional 504 shares during the last quarter. Finally, American International Group Inc. increased its stake in shares of Kymera Therapeutics by 6.4% during the first quarter. American International Group Inc. now owns 20,095 shares of the company’s stock worth $808,000 after purchasing an additional 1,209 shares during the period.

Analysts Set New Price Targets

Several research analysts have weighed in on KYMR shares. Oppenheimer increased their price objective on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, September 27th. Leerink Partners reiterated an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Monday, September 9th. Leerink Partnrs upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. Wells Fargo & Company lifted their price target on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a research report on Monday, August 12th. Finally, Truist Financial reissued a “buy” rating and set a $53.00 price target (down previously from $54.00) on shares of Kymera Therapeutics in a research report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $51.21.

Kymera Therapeutics Trading Down 8.7 %

KYMR stock opened at $41.96 on Friday. The firm has a 50-day moving average price of $47.17 and a 200-day moving average price of $41.62. Kymera Therapeutics, Inc. has a 12 month low of $16.94 and a 12 month high of $53.27. The stock has a market capitalization of $2.72 billion, a P/E ratio of -17.93 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.01. The business had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm’s revenue was down 20.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.90) EPS. As a group, equities analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $49.10, for a total transaction of $245,500.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Pamela Esposito sold 13,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The disclosure for this sale can be found here. 15.82% of the stock is currently owned by corporate insiders.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.